Biogen rises after beating annual profit estimates
06/02/2026 12:04
** Shares of drugmaker Biogen BIIB.O rise 1.26% to $187.69 premarket ** Co sees 2026 adj. profit of $15.25-$16.25/shr, above Wall Street's estimate of $14.92 ** Reports Q4 adj. profit of $1.99/shr vs analysts' average estimate of $1.59/shr - LSEG data ** Quarterly revenue $2.3 bln vs analysts' average expectation of $2.2 bln ** Shares up ~15% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout